Syneron Bio
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
ChinaFull profile →
Oral cyclic peptides · Companies
All cataloged matching companies in this field are shown below. Expand filters to narrow the results.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
79 matching companies
Oralead Pharma
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
ChinaFull profile →
Johnson & Johnson
FDA approved ICOTYDE for plaque psoriasis on 2026-03-17. Its prescribing information reports human exposure and food effects.
United StatesFull profile →
Chiesi / Chiasma heritage
A U.S. commercial benchmark for oral octreotide, with label evidence for enteric capsule composition and a substantial food effect. Its EU authorization has been withdrawn.
意大利 / United StatesFull profile →
Chugai Pharmaceutical
AUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
JapanFull profile →
Aurinia Pharmaceuticals
LUPKYNIS is a U.S.-approved oral treatment for lupus nephritis. Its capsule label discloses lipid and surfactant ingredients.
Canada / United StatesFull profile →
Protagonist
The discovery and collaboration partner for ICOTYDE. Its website also lists PN-881 (oral IL-17A/F) and other early oral programs; the company is recorded separately from J&J.
United StatesFull profile →
Circle Pharma
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
United StatesFull profile →
Unnatural Products
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
United StatesFull profile →
Insamo
The website explicitly focuses on cell-permeable, orally available cyclic peptides using machine learning, automated design, synthesis, and testing. No named clinical candidates were disclosed.
United States / 澳大利亚Full profile →
Vilya
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
United StatesFull profile →
Pinnacle Medicines
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
China / United StatesFull profile →
Orbis Medicines
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
丹麦 / SwitzerlandFull profile →
PeptiDream / ペプチドリーム
The PDPS-derived oral peptide pipeline includes a myostatin program listed as IND-enabling, plus other oral candidates; it is recorded separately from the radiopharmaceutical peptide pipeline.
JapanFull profile →
Hansoh Pharma
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
ChinaFull profile →
Avere Therapeutics
AVR-001 is Hansoh's HS-20118, with an exclusive license outside Greater China. A 2026 announcement proposed a merger with NextCure; the transaction is not recorded as closed.
United StatesFull profile →
Haisco Pharmaceutical
HSK47388 is an oral IL-23 inhibitory peptide in Phase 2 for psoriasis. Relative exposure data support its enhancer formulation, while cyclization and absolute oral bioavailability remain unconfirmed.
ChinaFull profile →
Salubris
SAL0167 is an internally developed cyclic peptide program for hyperlipidemia that received NMPA clinical trial authorization in 2026. Authorization is not treated as evidence of actual dosing.
ChinaFull profile →
Nogin AI
The website lists oral cyclic peptides NGA-101 (IL-4Rα), NGA-102 (TL1A), and NGA-103 (TSLP). Pipeline stage graphics cannot be verified through text extraction alone.
ChinaFull profile →
Guangzhou Dazhou Biomed
The MO-PION oral macromolecule platform website explicitly lists semaglutide, heparin, and micafungin applications. Micafungin provides a lead for cyclic peptide applications.
ChinaFull profile →
QIC / 큐아이씨
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
South KoreaFull profile →
D&D Pharmatech / 디앤디파마텍
ORALINK combines ligand conjugation, lipidation, and excipient strategies. The α4β7 cyclic peptide program with QIC is in lead optimization; its GLP-1 human evidence does not transfer to cyclic peptides.
South KoreaFull profile →
LG AI Research / LG AI연구원
Signed a next-generation oral peptide co-development agreement with D&D explicitly including macrocyclic peptides. Its role is AI design; independent ownership of a disclosed clinical drug has not been established.
South KoreaFull profile →
Inventage Lab / 인벤티지랩
The company disclosed a patent for an oral semaglutide nanoparticle formulation. This is a noncyclic peptide delivery reference, not clinical validation for cyclic peptides.
South KoreaFull profile →
Ensol Biosciences / 엔솔바이오사이언스
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
South KoreaFull profile →
AbbVie · Nimble Therapeutics
Co-commercializes approved LINZESS and holds regional rights, alongside oral peptide discovery through Nimble. ABBV-859 is in Phase 1; its exact structure and mapping to Nimble assets remain unconfirmed.
United StatesFull profile →
Gilead Sciences
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
United StatesFull profile →
PepStar Therapeutics Limited
Counterparty for the HCXT-2001 transaction. Its role is recorded separately from Gilead's; the shared candidate is not counted as two independent drugs. The relationship between the Chinese sponsor and English legal entity requires confirmation.
China（香港）Full profile →
Pepticom
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
Cyprumed
A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
AustriaFull profile →
Intract Pharma
Soteria provides protective excipients, Phloral provides targeted release, and UTAC provides active transport of macromolecules. Cyclic peptide applications require separate validation.
United KingdomFull profile →
Vivtex
The Novo collaboration uses gastrointestinal tissue screening and formulation platforms to develop oral biologics. Specific drugs and cyclic peptide structures have not been disclosed.
United StatesFull profile →
Enteris BioPharma
Peptelligence previously conducted feasibility studies with Ferring to convert injectable peptides into oral formulations. It is retained as a historical delivery approach; current operations and ownership require verification.
United StatesFull profile →
Entera Bio
EB613 is oral PTH(1-34), with disclosed clinical results and new-formulation bridging data and a planned Phase 3 program. Human evidence for this linear peptide is used only as a platform reference.
Rani Therapeutics
RaniPill is a swallowable robotic capsule. RT-101 octreotide is a historical human development program whose current activity is unconfirmed, recorded separately from conventional intestinal permeation enhancement.
United StatesFull profile →
Novartis
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
SwitzerlandFull profile →
Ironwood Pharmaceuticals
LINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
United StatesFull profile →
Bausch Health / Salix
TRULANCE (plecanatide) is an oral disulfide-constrained peptide and GC-C agonist acting locally in the gastrointestinal tract. Regional status is based on the Canadian product monograph reviewed.
Canada / United StatesFull profile →
Ferring Pharmaceuticals
Swallowed DDAVP desmopressin tablets are a classic oral disulfide peptide reference. Swallowed, orally disintegrating, and sublingual products should be recorded separately.
SwitzerlandFull profile →
Dayra Therapeutics
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
CanadaFull profile →
Biogen
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
United StatesFull profile →
argenx
Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.
Netherlands / Belgium / United StatesFull profile →
AstraZeneca
Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
United Kingdom / SwedenFull profile →
Novo Nordisk
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
Sungening Biotech
SG6001 is an oral PCSK9 cyclic peptide. Official materials confirm a preclinical program and an out-licensing strategy; clinical status of other antifungal candidates is not applied to this program.
ChinaFull profile →
Palatin Technologies
PL8177 is a colon-delivered cyclic heptapeptide MC1R agonist. The company reported Phase 2 UC proof of concept and explicitly welcomes partnerships / licensing.
United StatesFull profile →
Debiopharm
Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.
SwitzerlandFull profile →
XtalPi
PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
ChinaFull profile →
HitGen
The company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.
ChinaFull profile →
IRBM
Provides optimization of macrocyclic peptides derived from mRNA / phage display. Its website reports involvement in developing Merck's oral PCSK9 peptide MK-0616.
Curve Therapeutics
Microcycle® functionally screens compact macrocycles in live cells and develops macrocycle-derived drugs. This review did not confirm a named oral cyclic peptide candidate.
United KingdomFull profile →
Orbit Discovery
Its peptide screening platform covers linear, cyclic, and helical structures, so it is included as an adjacent discovery capability. It is not automatically classified as a validated oral cyclic peptide drug developer.
United KingdomFull profile →
Triastek
T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
ChinaFull profile →
Henlius
Original company materials confirm cyclic peptides as a development modality. This review did not find a primary announcement sufficient to verify a specific oral candidate and its current stage.
ChinaFull profile →
Sunshine Guojian
An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.
ChinaFull profile →
Sciwind Biosciences
The OralVantage™ oral peptide platform combines molecular stabilization and formulation strategies. It is included as a noncyclic peptide platform reference; validated oral cyclic peptides are not assumed.
ChinaFull profile →
Oralpeptime Biopharma
Founded in 2026, this early-stage oral long-acting peptide company describes molecular design, microbial expression, and OMV packaging / delivery. Cyclic peptide identity and human evidence require verification.
ChinaFull profile →
Bicycle Therapeutics
An important adjacent company in bicyclic peptide screening and conjugation. Its disclosed nonoral clinical pipeline is not evidence of oral cyclic peptide success.
United Kingdom / United StatesFull profile →
Hepion → Panetta Partners
Rencofilstat (CRV431) has oral clinical studies in MASH. Hepion transferred related assets to Panetta in 2025; the record preserves the historical development and change in rights.
United States / 权利承接方地域待核实Full profile →
Sublimity Therapeutics / Sigmoid heritage
ST-0529 is an oral cyclosporine formulation for UC with historical Phase 2 registration. The Romanian record reviewed is marked prematurely ended. Current ownership and company status require verification.
Sorriso Pharmaceuticals
SOR102 is a locally acting oral TNF / IL-23 bispecific single-domain antibody with a primary Phase 1 study. It is included as a noncyclic oral biologic reference.
United StatesFull profile →
Dr. Falk Pharma
The ST-0529 oral cyclosporine Phase 2 registry lists the company as a study supporter. That regional record ended prematurely; current development rights or collaboration budgets are not inferred.
GermanyFull profile →
Merck / MSD
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
United StatesFull profile →
Bachem
Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.
Switzerland / United StatesFull profile →
WuXi AppTec / WuXi TIDES
The website describes a client case for a non-GLP-1 oral cyclic peptide, from library synthesis and lead optimization through GMP preparation. Only service capability is recorded; the unnamed client is neither identified nor guessed.
China / United StatesFull profile →
Biosynth / Pepscan
CLIPS™ supports monocyclic, bicyclic, and tricyclic constrained peptides, screening, and optimization. Recorded at the integrated-group level; oral suitability requires program-level validation.
Switzerland / Netherlands / United StatesFull profile →
AmbioPharm
The company describes constrained peptide chemistry involving disulfides, lactam bridges, stapling, and other cyclization approaches. This review did not confirm a proprietary oral cyclic peptide candidate.
United States / ChinaFull profile →
Menten AI
MAUD 1.0 combines generative AI, physics-based modeling, and quantum simulations to design cyclic peptides. The company explicitly optimizes oral bioavailability and cell permeability and works with pharmaceutical partners on discovery.
United StatesFull profile →
Processa Pharmaceuticals
An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.
United StatesFull profile →
Generian Pharmaceuticals
A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
United StatesFull profile →
20n Bio
A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
United StatesFull profile →
Viva Biotech
Offers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
ChinaFull profile →
Astellas Pharma
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
JapanFull profile →
Grand Life Sciences (Beijing) Co., Ltd.
Ironwood’s Q2 2026 filing confirms that Grand Life Sciences assumed AstraZeneca’s linaclotide development, manufacturing, and commercialization rights in China, including Hong Kong and Macau, in May 2026.
ChinaFull profile →
Otsuka Pharmaceutical
Aurinia’s Q3 2026 filing identifies Otsuka as the development and commercialization partner for oral voclosporin in Japan, the EU, the UK, and other specified territories, supported by a commercial supply arrangement.
JapanFull profile →
Pharmaron
Provides cyclic and other complex peptide synthesis, noncanonical amino-acid modifications, peptide libraries, and in vitro oral-bioavailability screening. It is included as a discovery and development service provider.
ChinaFull profile →
Almac
Original technical materials describe macrocycle, stapled peptide, and bicyclic peptide synthesis. Included as discovery / manufacturing services, not elevated to an oral clinical drug developer.
United Kingdom / United StatesFull profile →
Asymchem
An original October 2026 investor record identifies oral cyclic peptides as a priority business and states that orders have been received. Only manufacturing services are recorded; proprietary drug pipelines are not inferred.
ChinaFull profile →
Porton Pharma
The TIDES platform covers process development, analytics, and manufacturing for monocyclic, polycyclic, and modified peptides. This review did not confirm a named oral cyclic peptide program.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.